Physician profile
Christopher Dimaio
NPI 1295930840
$36,757.13
in general payments reported to CMS, 2019-2025
11 companies · $46.15 in 2025
The $46.15 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,181 · 2020: $12K · 2021: $4,046 · 2022: $14K · 2023: $219 · 2024: $281 · 2025: $46.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $20,320.52 | 2019-2024 | Orcapod, Compliance Endokit, Resolution Clip |
| Abbvie INC. | $7,075.93 | 2020-2024 | Creon |
| US Endoscopy | $5,850.00 | 2020-2021 | |
| Mauna Kea Technologies, INC. | $2,250.00 | 2020 | |
| Pinnacle Biologics, INC | $500.00 | 2021 | |
| Cook Medical LLC | $234.64 | 2019-2021 | |
| Conmed Corporation | $206.74 | 2023-2025 | Conmed Biliary, Conmed Generators |
| 3-D Matrix, INC. | $159.93 | 2023-2024 | |
| Medtronic, INC. | $110.00 | 2021 | |
| Aimmune Therapeutics, INC. | $28.56 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $20.81 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Dimaio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.